-74%

est. 2Y upside i

HealthcareSeed

AI RCM. A/R Analysis in 3 days or less. Reduce claim denials by 55%.

Rank

#432

Sector

Healthtech

Est. Liquidity

~6Y

Data Quality

Data: Medium

Ember is a promising seed-stage healthtech company with a strong competitive moat through its proprietary AI, demonstrating significant results in reducing healthcare denials and increasing net collections.

Last updated: March 10, 2026

Bull (30%)+350%

Ember's proprietary AI achieves widespread adoption across major health systems, becoming the industry standard for denial prevention and RCM. Strategic partnerships and continued innovation push revenue to over $100M by 2028, justifying a $112.5M+ valuation at a premium multiple due to its strong competitive moat and proven ROI.

Base (40%)+100%

Ember successfully captures a significant niche in the AI-native RCM market, growing steadily by expanding its customer base and product features. It reaches approximately $40M in revenue by 2028, leading to an acquisition or Series B/C round at a $50M valuation, providing a moderate return for early equity holders.

Bear (30%)-80%

Dominant incumbents like Microsoft or Experian Health launch highly competitive, well-resourced AI RCM solutions, eroding Ember's market share and pricing power. Growth stalls, and the company struggles to raise subsequent funding rounds, leading to a down round or acquisition at a distressed valuation of $5M, wiping out most common stock value due to liquidation preferences.

Est. time to liquidity~6.0 years

Preference Stack Risk

high

Investors hold $5M in liquidation preferences, meaning common stock holders are behind this amount in an exit scenario.

Dilution Risk

high

As a seed-stage company, Ember will likely require several more funding rounds, leading to significant future dilution for early equity holders.

Secondary Liquidity

none

There is currently no active secondary market or tender offers for Ember's equity due to its early stage.

Questions to Ask at the Interview

Strategic questions based on Ember's data — designed to show you've done your homework.

  • 1

    “How does Ember plan to continuously differentiate its proprietary AI and maintain its accuracy advantage against large incumbents like Microsoft and Experian Health, especially as they invest more heavily in AI for RCM?”

  • 2

    “Given the impressive results in denial reduction and net collection rates, what is Ember's strategy for scaling customer acquisition beyond initial large health systems and penetrating the broader SAM of $36.1B?”

  • 3

    “As a seed-stage company with a 20% preference stack, how is the company thinking about managing future dilution and ensuring that common stock holders see meaningful returns in potential exit scenarios over the next 5-7 years?”

Community

Valuation Sentiment

Our model estimates -74% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.